Budralazine | CAS#36798-79-5 | antihypertensive

MedKoo Cat#: 584294 | Name: Budralazine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Budralazine is an antihypertensive drug.

Chemical Structure

Budralazine

CAS#36798-79-5

Theoretical Analysis

MedKoo Cat#: 584294

Name: Budralazine

CAS#: 36798-79-5

Chemical Formula: C14H16N4

Exact Mass: 240.1375

Molecular Weight: 240.31

Elemental Analysis: C, 69.97; H, 6.71; N, 23.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Budralazine; Buterazine

IUPAC/Chemical Name

4-Methyl-3-penten-2-one (1-phthalazinyl)hydrazone

InChi Key

DQGFCLJXYFXXIJ-LFIBNONCSA-N

InChi Code

InChI=1S/C14H16N4/c1-10(2)8-11(3)16-18-14-13-7-5-4-6-12(13)9-15-17-14/h4-9H,1-3H3,(H,17,18)/b16-11+

SMILES Code

CC(/C=C(C)\C)=N\NC1=NN=CC2=C1C=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 240.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Konno K, Nonaka K, Ueno A. Hypotensive and cardiovascular action of budralazine in unanesthetized and unrestrained dogs. Arzneimittelforschung. 1981;31(7):1072-5. PubMed PMID: 7196755. 2: Hagihara Y. [Effect of 4-methyl-3-penten-2-one (1-phthalazinyl) hydrazone (budralazine) on intra- and extracranial circulation in cats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Jan;77(1):41-50. Japanese. PubMed PMID: 7262706. 3: Yoshioka M, Yahagi H, Minami M, Saito H. Central sympathoinhibitory action of a direct-acting vasodilator, budralazine, in anesthetized rats. Jpn J Pharmacol. 1987 Jun;44(2):187-96. PubMed PMID: 3656776. 4: Fujimaki Y, Hakusui H, Takegoshi T. Quantitative analysis of budralazine in human plasma and urine by gas chromatography-mass spectrometry. J Chromatogr. 1987 Oct 30;421(2):367-71. PubMed PMID: 3429588. 5: Tanaka S, Tanaka M, Akashi A. [Effect of an antihypertensive drug, budralazine, on the cerebral circulation in spontaneously hypertensive rats]. Nihon Yakurigaku Zasshi. 1986 Jun;87(6):655-63. Japanese. PubMed PMID: 3744171. 6: Chiba T, Shibamura S, Tanaka M, Yamasaki T, Hashimoto H, Kurebayashi Y, Kasai Y, Ryokawa Y, Tamura K, Hirohashi M, Akashi A. Antihypertensive and general pharmacological properties of budralazine. Arzneimittelforschung. 1981;31(7):1080-7. PubMed PMID: 7023495. 7: Yoshioka M, Minami M, Saito H. The anti-tachycardic mechanism of a direct-acting vasodilator, budralazine, in rats. Clin Exp Hypertens A. 1991;13(5):1107-14. PubMed PMID: 1773498. 8: Tanaka S, Ashida S, Akashi A. Effects of antihypertensive drugs on experimental cerebral ischemia in spontaneously hypertensive rats. Jpn J Pharmacol. 1990 Aug;53(4):502-5. PubMed PMID: 2214372. 9: Kitamura J, Mori H, Sugie S, Kawai K. Genetic toxicity of several antihypertensive drugs possessing a hydrazine group. Res Commun Chem Pathol Pharmacol. 1985 Sep;49(3):415-22. PubMed PMID: 4059657. 10: Shibamura S, Chiba T, Suzuki I, Akashi A. Pre- and postsynaptic alpha-adrenergic effects of the antihypertensive drug budralazine. Arzneimittelforschung. 1981;31(7):1076-9. PubMed PMID: 6268123. 11: Higashio T, Tsuji Y, Nakao K, Sakaguchi S, Tanaka M. Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. Arzneimittelforschung. 1988 Mar;38(3):350-8. PubMed PMID: 3382459. 12: Ono K, Saito T, Sasano H, Moroi R, Sano M, Akimoto T. Metabolism of budralazine, a new antihypertensive agent, III. Xenobiotica. 1979 Apr;9(4):227-36. PubMed PMID: 483859. 13: Tanaka S, Ishihara M, Shibamura S, Sekiguchi F, Hirohashi M, Shirasaki Y, Akashi A. [The effect of an antihypertensive drug budralazine on cerebrovascular lesions in salt-loaded SHR]. Nihon Yakurigaku Zasshi. 1989 Jul;94(1):49-60. Japanese. PubMed PMID: 2792961. 14: Chiba T, Hirohashi M, Suzuki I, Tanaka S, Watanabe K, Akashi A. Characterization of the vasodilator action of antihypertensive drug budralazine. Arzneimittelforschung. 1983;33(1):112-6. PubMed PMID: 6299307. 15: Parravicini F, Scarpitta G, Dorigotti L, Pifferi G. [3-Hydrazinepyridazine derivatives. III. Synthesis and anti-hypertensive activity of new 3-(2-acylhydrazine)-pyridazine-6-alkylamino substitutes]. Farmaco Sci. 1979 Apr;34(4):299-310. Italian. PubMed PMID: 553832. 16: Shirasaki Y, Masumura H, Akashi A. [Effect of an antihypertensive drug, budralazine, on glucose and lipid metabolism in diabetic SHR]. Nihon Yakurigaku Zasshi. 1986 Mar;87(3):301-11. Japanese. PubMed PMID: 3710313. 17: Chiba S, Saegusa K, Furukawa Y, Ogiwara Y. Cardiovascular effects of budralazine in the dog. Jpn Heart J. 1986 May;27(3):403-11. PubMed PMID: 3761571. 18: Minami M, Togashi H, Sano M, Saito I, Morii K, Nomura A, Yoshioka M, Saito H. [Effects of a new vasodilator, budralazine on water drinking activity, plasma norepinephrine, plasma angiotensin II, plasma arginine vasopressin, plasma serotonin concentration, urinary aldosterone excretion rate and urinary catecholamine excretion rate in rats]. Hokkaido Igaku Zasshi. 1985 Nov;60(6):856-64. Japanese. PubMed PMID: 4085968. 19: Tanaka S, Tanaka M, Akashi A. Influence of antihypertensive treatment with budralazine on autoregulation of cerebral blood flow in spontaneously hypertensive rats. Stroke. 1989 Dec;20(12):1724-9. PubMed PMID: 2595735. 20: Ogihara T, Morimoto S, Nakahashi T, Hiwada K, Matsuoka H, Matsumoto M, Shimamoto K, Onchi Y, Abe I, Mikami H, Ishimitsu T, Kohara K, Takizawa S, Takasaki M, Masuda A, Munehira J, Eto M, Takagawa Y, Kiyohara Y, Ibayashi S, Nakamura T, Fujishima M. [Multicenter prospective survey of prognosis of hypertensive elderly outpatient under antihypertensive treatment--morbidity and mortality of cardiovascular diseases and cancer]. Nihon Ronen Igakkai Zasshi. 1999 May;36(5):342-52. Japanese. PubMed PMID: 10466352.